Patient-Friendly Explanation
Off-label prescribing means a doctor uses a medicine that is approved for another condition to help with weight, because the evidence supports it. Examples include diabetes medicines and some epilepsy or migraine medicines that also reduce appetite or body weight. It is legal and can be appropriate, but the evidence, side effects and monitoring differ from medicines approved specifically for weight management.
Clinical Definition
Off-label use refers to prescribing outside a regulator’s approved indication; in obesity this includes metformin for insulin resistance, topiramate and zonisamide for appetite and craving, and older anti-obesity agents where licensed alternatives are unavailable or unaffordable. Prescribing requires informed consent, a documented rationale, attention to dose-dependent adverse effects such as metabolic acidosis, nephrolithiasis, cognitive slowing and teratogenicity, and monitoring of weight, renal function and mental health with clear stopping rules. Off-label use should support, not replace, dietary, behavioural and physical activity treatment.
Why It Matters
Patients often hear about these medicines from social media or friends and may obtain them without any assessment, so understanding the difference between an approved indication and a considered off-label trial helps them weigh benefit against risk. NuLifeCare Singapore doctors discuss off-label options openly, document the rationale and set a review date, and never present them as equivalent to licensed weight-management therapy.